Latest Healthcare News

Ansell Limited (ASX:ANN) reported a robust FY26 with net profit doubling to US$208.6 million, driven by strong sales growth and operational resilience amid geopolitical challenges. The company also announced a leadership change and reaffirmed its sustainability ambitions.

Charter Hall Social Infrastructure REIT (ASX:CQE) posted a robust FY26 result with a 13.1% rise in operating earnings per unit, driven by strategic acquisitions and disciplined capital recycling. The portfolio now boasts a $2.3 billion valuation, near-full occupancy, and extended lease terms, underpinning income resilience amid ongoing sector demand.

Charter Hall Long WALE REIT (ASX:CLW) reported steady operating earnings growth and reinforced its long WALE portfolio quality for FY26, alongside a $2 billion debt refinancing and enhanced sustainability credentials.

Arena REIT reported an 8% rise in net operating profit to $79.1 million for FY2026, driven by rental growth and development completions, while facing uncertainty over its Edge Early Learning Portfolio due to rent defaults.

Pro Medicus' US arm, Visage Imaging, has landed a substantial 7-year, A$25 million contract to deploy its Visage 7 cloud-based imaging platform across Valley Health's hospital network in Virginia and West Virginia.

Fisher & Paykel Healthcare has raised its full-year net profit guidance for FY2027, buoyed by robust first-half sales and a $23 million US tariff refund. The medical devices maker forecasts up to 24% profit growth in H1, driven by hospital product demand and operational efficiencies.

Excite Technology Services (ASX: EXT) has secured $3.122 million in sales over June and July 2026, bolstered by government contracts and private sector recurring revenue. The company is also tapping into a growing AI cybersecurity market with a pipeline exceeding $200,000.

Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.

Emyria has cleared a key operational hurdle by resolving Authorised Prescriber capacity constraints in Perth and Queensland, enabling a planned expansion of treatment days in Q4 2026 through the recruitment of 15 new therapists.

Memphasys has cleared a key regulatory hurdle in Vietnam for its Felix™ System, prompting a significant first commercial cartridge order and marking early clinical success in a fast-growing fertility market.

Dexus (ASX: DXS) reported steady FY26 results with AFFO of 45.0 cents per security and distributions of 37.0 cents, while initiating a strategic review of infrastructure funds following an adverse APAC court judgment.

NAOS Emerging Opportunities Company Limited (ASX: NCC) delivered a robust FY26 with a 2416% surge in after-tax profit and an 18.7% portfolio return, outperforming the benchmark by over 10%. The company raised its fully franked dividend by 5%, signaling confidence amid a challenging market.